Kiromic Biopharma is an immuno-oncology, target discovery, and gene editing company developing highly effective and safe tumor-specific cancer engineered immunotherapies to face and defeat multiple cancer types. They are focused on extending the benefits of immunotherapy by leveraging DIAMOND AI (Kiromic Diamond Artificial Intelligence), which is a multi-purpose computational platform that can identify new cancer immunological targets for T-Cells and B-Cells.

Biotechnology

Kiromic Biopharma

Brian Hungerford

Alan Guerrero

Diane Duyen Nguyen

Leonardo Mirandola

Scott Dahlbeck

Lucia Piccotti

Sarah Madonna

Raquel Dien

Trish Faulkner

The Leadership Team at Kiromic Biopharma drives the strategic direction and vision of the company, overseeing the development of innovative cancer therapies. Comprised of industry experts, including the CEO and Chief Medical Officer, the team is responsible for advancing research initiatives, fostering collaborations, and ensuring the integration of DIAMOND AI into the company’s operations to enhance target discovery and therapeutic efficacy in immuno-oncology.

Leadership Team

Scientific Research and Operations

Scientific Advisory

Leadership Team

About

Team members

Other teams at Kiromic Biopharma

Scientific Research and Operations

Scientific Advisory